How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

241 results for

Rheumatoid Arthritis Antiinflammatory Medications

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Rheumatoid Arthritis Antiinflammatory Medications

Rheumatoid Arthritis Antiinflammatory Medications Rheumatoid Arthritis Antiinflammatory Medications Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer (...) Administration 4 Rheumatoid Arthritis Antiinflammatory Medications Rheumatoid Arthritis Antiinflammatory Medications Aka: Rheumatoid Arthritis Antiinflammatory Medications From Related Chapters II. Indications: Rheumatoid Arthritis Symptom relief and improved function No change in progression are first line agents The anti-inflammatory agents shown here are adjuncts to therapy Limit use of s and s once on >1 month Decrease to lowest effective dose (preferably use only as needed) Best use is limiting S and s

2018 FP Notebook

2. Diet and Rheumatoid Arthritis Symptoms: Survey Results From a Rheumatoid Arthritis Registry. (PubMed)

Diet and Rheumatoid Arthritis Symptoms: Survey Results From a Rheumatoid Arthritis Registry. Patients with rheumatoid arthritis (RA) often ask whether specific foods, popularized as inflammatory or antiinflammatory, can improve or worsen their RA. Patients with RA took a survey on diet and RA symptoms, and the survey data were collected and analyzed.A dietary survey was mailed to 300 subjects in a single-center RA registry at a large academic center. Subjects were asked about their consumption (...) of 20 foods and whether these foods make their RA symptoms better, worse, or unchanged. Semiannual registry data include demographics, medications, comorbidities, and disease activity scores. Fisher's exact test and Wilcoxon's rank sum tests evaluated associations between subject characteristics from the most recent registry assessment and changes in RA symptoms from specific foods.Of the 217 subjects (72% response rate), 83% were female; the median RA duration was 17 years (interquartile range 9-27

Full Text available with Trip Pro

2017 Arthritis care & research

3. The Rate of Adherence to Antiarthritis Medications and Associated Factors among Patients with Rheumatoid Arthritis: A Systematic Literature Review and Metaanalysis. (PubMed)

The Rate of Adherence to Antiarthritis Medications and Associated Factors among Patients with Rheumatoid Arthritis: A Systematic Literature Review and Metaanalysis. Reported adherence in rheumatoid arthritis (RA) varies widely (10.5-98.5%). Variability may result in part from different methods used to measure adherence. Our aims were to quantify adherence to antiarthritis medications for each method and to identify variability and associated factors.The systematic literature review examined (...) PubMed, the Cochrane central database, and article reference lists from 1970 to November 2014. Papers with medication adherence data (disease-modifying antirheumatic drugs, steroids, and nonsteroidal antiinflammatory drugs) in adult patients with RA or data on associated factors were included. Adherence rate was recorded for each method. Random-effect metaanalysis estimated adherence for different evaluation methods.Adherence rate was 66% (95% CI 0.58-0.75). There were no differences in adherence

2016 Journal of Rheumatology

4. American College of Rheumatology Guidelines for Management of Gout Part 2: Therapy and Antiinflammatory Prophylaxis of Acute Gouty Arthritis

American College of Rheumatology Guidelines for Management of Gout Part 2: Therapy and Antiinflammatory Prophylaxis of Acute Gouty Arthritis 2012 American College of Rheumatology Guidelines for Management of Gout. Part 2: Therapy and Antiin?ammatory Prophylaxis of Acute Gouty Arthritis DINESH KHANNA, 1 PUJA P. KHANNA, 1 JOHN D. FITZGERALD, 2 MANJIT K. SINGH, 3 SANGMEE BAE, 2 TUHINA NEOGI, 4 MICHAEL H. PILLINGER, 5 JOAN MERILL, 6 SUSAN LEE, 7 SHRADDHA PRAKASH, 2 MARIAN KALDAS, 2 MANEESH GOGIA, 2 (...) Levy, MD, MBA: South- ern California Permanente Medical Group, Downey; 19 N. Lawrence Edwards, MD: University of Florida, Gainesville; 20 Brian Mandell, MD, PhD: Cleveland Clinic, Cleveland, Ohio; 21 H. Ralph Schumacher, MD: VA Medical Center and Arthritis Care & Research Vol. 64, No. 10, October 2012, pp 1447–1461 DOI 10.1002/acr.21773 © 2012, American College of Rheumatology SPECIAL ARTICLE 1447guidelines to treat hyperuricemia in patients with evi- dence of gout (or gouty arthritis) (1). Gout

2012 American College of Rheumatology

5. Salazopyrine (A07EC01 (intestinal anti-inflammatory agents)) - Ulcerative colitis, Crohn's disease in the colon, Rheumatoid arthritis

Salazopyrine (A07EC01 (intestinal anti-inflammatory agents)) - Ulcerative colitis, Crohn's disease in the colon, Rheumatoid arthritis HAS - Medical, Economic and Public Health Assessment Division 1/15 The legally binding text is the original French version T TR RA AN NS SP PA AR RE EN NC CY Y C CO OM MM MI IT TT TE EE E Opinion 23 July 2014 SALAZOPYRINE 500 mg, tablet Bottle of 100 tablets - CIP code: 322 688-0 Applicant: PFIZER INN Sulfasalazine ATC Code (2014) A07EC01 (intestinal anti (...) -inflammatory agents) Reason for the review Renewal of inclusion List concerned National Health Insurance (French Social Security Code L.162-17) Indications concerned "Gastroenterology: Ulcerative colitis: treatment of attacks and prevention of relapses. Crohn's disease in the colon. Rheumatology: Rheumatoid arthritis." HAS - Medical, Economic and Public Health Assessment Division 2/15 01 ADMINISTRATIVE AND REGULATORY INFORMATION Marketing Authorisation (national procedure) Date initiated: 31 March 1992

2015 Haute Autorite de sante

6. Trolovol (D-penicillamine) - Disease-modifying treatment of rheumatoid arthritis, Treatment of Wilson's disease

Trolovol (D-penicillamine) - Disease-modifying treatment of rheumatoid arthritis, Treatment of Wilson's disease HAS - Medical, Economic and Public Health Assessment Division 1/7 The legally binding text is the original French version T TR RA AN NS SP PA AR RE EN NC CY Y C CO OM MM MI IT TT TE EE E Opinion 23 July 2014 TROLOVOL 300 mg, film-coated tablet B/30 (CIP: 34009 320 316 9 6) Applicant: IMAXO INN D-penicillamine ATC Code (2012) M01CC01 (Specific antirheumatic agents) Reason (...) for the review Renewal of inclusion List concerned National Health Insurance (French Social Security Code L.162-17) Indications concerned "Disease-modifying treatment of rheumatoid arthritis Treatment of Wilson's disease." HAS - Medical, Economic and Public Health Assessment Division 2/7 01 ADMINISTRATIVE AND REGULATORY INFORMATION Marketing Authorisation (national) Initial date (national): 6 September 1976 validated on 17 February 1998 Prescribing and dispensing conditions/special status List I ATC

2015 Haute Autorite de sante

7. Nivaquine (Chloroquine) - Long-acting symptomatic treatment of rheumatoid arthritis

– moving annual total) show that 17,631 prescriptions were issued for NIVAQUINE. This small number of prescriptions does not allow a reliable analysis to be made of these data, particularly by indication. There are no data on the use of this proprietary medicinal product in RA. HAS – Medical, Economic and Public Health Assessment Division 4/5 04.4 Therapeutic use Rheumatoid arthritis The management of rheumatoid arthritis at present consists of the prescription of an immediate-acting antiinflammatory (...) Nivaquine (Chloroquine) - Long-acting symptomatic treatment of rheumatoid arthritis HAS – Medical, Economic and Public Health Assessment Division 1/5 The legally binding text is the original French version T TR RA AN NS SP PA AR RE EN NC CY Y C CO OM MM MI IT TT TE EE E Opinion 23 July 2014 NIVAQUINE 100 mg, scored tablet B/20 (CIP: 34009 307 311 7 8) B/100 (CIP: 34009 307 310 0 0) Applicant: SANOFI-AVENTIS France INN Chloroquine ATC code (2014) P01BA01 (synthetic antimalarials) Reason

2015 Haute Autorite de sante

8. Acadione (Tiopronin) - Disease-modifying treatment of rheumatoid arthritis. Treatment of cystine lithiasis

Acadione (Tiopronin) - Disease-modifying treatment of rheumatoid arthritis. Treatment of cystine lithiasis HAS - Medical, Economic and Public Health Assessment Division 1/5 The legally binding text is the original French version T TR RA AN NS SP PA AR RE EN NC CY Y C CO OM MM MI IT TT TE EE E Opinion 23 July 2014 ACADIONE 250 mg, sugar-coated tablet Bottle of 120 (CIP: 34009 329 390 7 7) Applicant: SANOFI-AVENTIS France INN Tiopronin ATC Code (2014) M01CX: Other specific antirheumatic drugs (...) Reason for the review Renewal of inclusion List concerned National Health Insurance (French Social Security Code L.162-17) Indications concerned "Disease-modifying treatment of rheumatoid arthritis Treatment of cystine lithiasis." HAS - Medical, Economic and Public Health Assessment Division 2/5 01 ADMINISTRATIVE AND REGULATORY INFORMATION Marketing Authorisation (national procedure) Date initiated: 1 st September 1977 Prescribing and dispensing conditions/special status List I ATC Classification

2015 Haute Autorite de sante

9. Renal Manifestations of Rheumatoid Arthritis. (PubMed)

Renal Manifestations of Rheumatoid Arthritis. Renal manifestations in rheumatoid arthritis (RA) have evolved as RA management has improved. In the past, older disease-modifying antirheumatic drugs, uncontrolled systemic inflammation, and chronic nonsteroidal antiinflammatory drug (NSAID) use contributed to kidney disease. Over time, the use of methotrexate and biologic medications, decrease in NSAID use, and a treat-to-target strategy have contributed to a decrease in renal manifestations

2018 Rheumatic Diseases Clinics of North America

10. Management of early rheumatoid arthritis

but for a significant number of patients it is a severe disease resulting in persistent pain and stiffness, progressive joint destruction, functional decline and premature mortality. 1-3 There is also the potential loss of social and financial independence 4 and the burden of care on direct (eg medical care) and indirect costs (eg effects on the individual’s ability to work). 5, 6 The goal of early treatment for rheumatoid arthritis is to achieve clinical and radiological remission and reduce functional limitations (...) and progressive rheumatoid arthritis in adults not previously treated with methotrexate or other DMARDs is not recommended. 2 KEY MESSAGES2 ++ 2 ++ 2 - 4 3 Diagnosis of early rheumatoid arthritis The diagnosis of early RA relies heavily on the accurate interpretation of medical history and clinical examination, and is informed by clinical investigations. The American College of Rheumatology (ACR) and the European League Against Rheumatism (EULAR) 2010 criteria for the classification of RA illustrates this. 8

2011 SIGN

11. Rheumatoid Arthritis Antiinflammatory Medications

Rheumatoid Arthritis Antiinflammatory Medications Rheumatoid Arthritis Antiinflammatory Medications Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer (...) Administration 4 Rheumatoid Arthritis Antiinflammatory Medications Rheumatoid Arthritis Antiinflammatory Medications Aka: Rheumatoid Arthritis Antiinflammatory Medications From Related Chapters II. Indications: Rheumatoid Arthritis Symptom relief and improved function No change in progression are first line agents The anti-inflammatory agents shown here are adjuncts to therapy Limit use of s and s once on >1 month Decrease to lowest effective dose (preferably use only as needed) Best use is limiting S and s

2015 FP Notebook

12. Comparative Clinical Trial of Efficacy and Safety of BCD-055 and Remicade® in Combination With Methotrexate in Patients With Active Rheumatoid Arthritis

rheumatoid arthritis according to criteria of American College of Rheumatologists (2010), that was diagnosed at least 6 months prior to screening. Active rheumatoid arthritis at screening despite of therapy with methotrexate for 3 last months. Use of methotrexate in stable dose for at least 4 weeks before screening (10-25 mg per week). History of ineffective treatment with basic antiinflammatory drugs (including methotrexate). Exclusion Criteria: Previous therapy of rheumatoid arthritis with monoclonal (...) Comparative Clinical Trial of Efficacy and Safety of BCD-055 and Remicade® in Combination With Methotrexate in Patients With Active Rheumatoid Arthritis Comparative Clinical Trial of Efficacy and Safety of BCD-055 and Remicade® in Combination With Methotrexate in Patients With Active Rheumatoid Arthritis - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail

2016 Clinical Trials

13. A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ASP5094 Following Multiple Intravenous Doses in Subjects With Rheumatoid Arthritis on Methotrexate

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ASP5094 Following Multiple Intravenous Doses in Subjects With Rheumatoid Arthritis on Methotrexate A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ASP5094 Following Multiple Intravenous Doses in Subjects With Rheumatoid Arthritis on Methotrexate - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms (...) x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ASP5094 Following Multiple Intravenous Doses in Subjects With Rheumatoid Arthritis on Methotrexate The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been

2016 Clinical Trials

14. Subfertility in rheumatoid arthritis is often unexplained or caused by anovulation. (PubMed)

who were pregnant or trying to conceive between 2002 and 2010 (Pregnancy-Induced Amelioration of Rheumatoid Arthritis Study). Patients who had given consent for future contact (n = 260) received a questionnaire on reproductive history, fertility examinations, and fertility treatments. Medical files were obtained from attending gynecologists.A completed questionnaire was returned by 178 women (68%), of whom 96% had ended their efforts to conceive. Eighty-two subjects (46%) had at least 1 subfertile (...) Subfertility in rheumatoid arthritis is often unexplained or caused by anovulation. Subfertility is frequently encountered among female rheumatoid arthritis (RA) patients and has been associated with disease activity and antirheumatic drugs. However, little is known about the results of the fertility assessments in these women. Our aim was to study the outcome of fertility assessments in subfertile women with RA.A cross-sectional study was performed in a nationwide cohort of female RA patients

Full Text available with Trip Pro

2016 Arthritis care & research

15. Remaining pain is common in early rheumatoid arthritis patients treated with methotrexate. (PubMed)

response), and 45% (no response).These results are in line with the hypothesis that a subgroup of early RA patients exhibits pain that is not inflammatory mediated, where alternative treatment strategies to traditional antiinflammatory medications need to be considered.© 2016 The Authors. Arthritis Care & Research published by Wiley Periodicals, Inc. on behalf of the American College of Rheumatology. (...) Remaining pain is common in early rheumatoid arthritis patients treated with methotrexate. To investigate the frequency of remaining pain in early rheumatoid arthritis (RA) after 3 months of treatment with methotrexate as the only disease modifying antirheumatic drug, with a special focus on patients with a good clinical response.The study base was cases reported to a population-based early RA cohort who had followup data from the Swedish Rheumatology Quality Register (n = 1,241). The Disease

Full Text available with Trip Pro

2016 Arthritis care & research

16. CRACKCast E116 – Arthritis

inflammatory reaction. Contiguous spread can also occur through direct trauma. [1] List a differential diagnosis (4 for each) for monoarticular, polyarticular symmetrical, and polyarticular asymmetrical arthritis. If the site of the patient’s pain is articular, classifying whether the arthritis is monoarticular (eg, septic arthritis or gout) or polyarticular may aid in diagnosis. Polyarticular arthritis may be symmetrical (eg, rheumatoid or drug-induced) or asymmetrical (eg, rubella, acute rheumatic fever (...) Rheumatoid arthritis flare Psoriatic arthritis Polymyalgia rheumatica Enteric arthritis Ankylosing spondylitis Hep B/C induced arthritis Gonococcal arthritis Lyme arthritis ARF Reactive arthritis Viral arthritides ARF, Acute rheumatic fever; CPPD, calcium pyrophosphate dihydrate deposition Disease. [2] What are systemic signs of arthritis? List extraarticular manifestations of RA. TABLE 106.2: Systemic Signs of Arthritis Diseases* Organ System Findings Diseases Airway Airway Obstruction RA, relapsing

2017 CandiEM

17. Interventional Spine and Pain Procedures in Patients on Antiplatelet and Anticoagulant Medications

Interventional Spine and Pain Procedures in Patients on Antiplatelet and Anticoagulant Medications Interventional Spine and Pain Procedures in Patients on Anti... : Regional Anesthesia and Pain Medicine You may be trying to access this site from a secured browser on the server. Please enable scripts and reload this page. Login No user account? Lippincott Journals Subscribers , use your username or email along with your password to log in. Remember me on this computer Register for a free account (...) procedures were published in 2015. Recent reviews evaluating bleeding complications in patients undergoing specific interventional pain procedures, the development of new regional anesthesia and acute pain guidelines, and the development of new anticoagulants and antiplatelet medications necessitate complementary updated guidelines. The authors desired coordination with the authors of the recently updated regional and acute pain anticoagulation guidelines. The latest evidence was sought through extensive

2018 American Society of Regional Anesthesia and Pain Medicine

18. Rheumatoid arthritis

for Health and Care Excellence (NICE) guidelines Rheumatoid arthritis in adults: management [ ], Rheumatoid arthritis: national clinical guideline for management and treatment in adults [ ], the American College of Rheumatology (ACR) Guideline for the treatment of rheumatoid arthritis [ ], the European League Against Rheumatism (EULAR) 2016 update of the EULAR recommendations for the management of early arthritis [ ], the British Medical Journal (BMJ) best practice guide Rheumatoid Arthritis [ ], expert (...) the review of this topic. Audit criteria Audit criteria No audit criteria were found during the review of this topic. QOF indicators QOF indicator Table 1 . Indicators related to rheumatoid arthritis in the Quality and Outcomes Framework (QOF) of the General Medical Services (GMS) contract. Indicator Points Achievement thresholds RA001 The practice establishes and maintains a register of patients aged 16 or over with rheumatoid arthritis 1 - RA002 The percentage of people with rheumatoid arthritis

2013 NICE Clinical Knowledge Summaries

19. The prevalence of renal impairment in patients with rheumatoid arthritis: Results from the COMEDRA study. (PubMed)

The prevalence of renal impairment in patients with rheumatoid arthritis: Results from the COMEDRA study. To assess the prevalence and associations of renal dysfunction in patients with rheumatoid arthritis (RA).COMEDRA is a French nationwide cross-sectional multicenter study on comorbidities in RA. Renal function was assessed from the estimated glomerular filtration rate (eGFR), using the Modification of Diet in Renal Disease equation. RA characteristics and risk factors for renal impairment (...) ) and 9% had proteinuria. In univariate analysis, renal impairment was associated with age (P < 0.001), history of hypertension (P < 0.001), high systolic blood pressure (P = 0.03), and the Systematic Coronary Risk Evaluation (SCORE) equation (P = 0.002), but not with sex, disease duration, disease activity (as assessed by DAS28-ESR), nonsteroidal antiinflammatory drug use, disease severity (erosions, joint replacement), or RA medications. Multivariate analysis models showed that age (odds ratio

Full Text available with Trip Pro

2015 Arthritis care & research

20. Efficacy, Safety and Pharmacokinetics of BIRB 796 BS Tablets in Patients With Active Rheumatoid Arthritis

Efficacy, Safety and Pharmacokinetics of BIRB 796 BS Tablets in Patients With Active Rheumatoid Arthritis Efficacy, Safety and Pharmacokinetics of BIRB 796 BS Tablets in Patients With Active Rheumatoid Arthritis - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100 (...) ). Please remove one or more studies before adding more. Efficacy, Safety and Pharmacokinetics of BIRB 796 BS Tablets in Patients With Active Rheumatoid Arthritis The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT02214888 Recruitment Status : Terminated First Posted : August 13, 2014 Last Update Posted

2014 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>